Free Newsletter
Swine flu outbreak could translate into PR coup
The swine flu outbreak may be just what the pharma marketing folks need to help in their makeover of a badly tainted image.
A few years ago the vaccine industry was in disarray. But big manufacturers have jumped into the field, investing huge sums and pushing more efficient manufacturing processes. As a result, flu vaccine production has been greatly expanded and many of these global operations stand to reap a huge PR reward if they can meet expectations during this outbreak.
"It's not really about earnings accretion in 2009, it's about political goodwill with governments across the world for addressing one of the most acute public health concerns in recent history," said UBS pharmaceuticals analyst Gbola Amusa. "That political goodwill is exceptionally valuable for these pharma companies."
- read the report from the Guardian
Related Articles:
Two flu drugs better than one
Clamor for flu drugs clears store shelves
Big challenge looms over swine flu vax production
Roche, Glaxo ramping up on flu meds
Biotech companies scramble as swine flu spreads
Comments
By Anonymous | Posted 2:06am | May 21, 2009
Are you guys going to mention anything about Baxter International mixing live avian flu virus (H5N1) with regular seasonal flu virus (H3N2) vaccines in their products? It is all over other countries but not is the US....
Post new comment
Paid Research Reports
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
- Pharmaceuticals: United States Industry Guide
- Generic Benchmarking: Brand Erosion at Patent Expiry
- Key Players in Pharmaceutical Contract Manufacturing: Market developments, outsourcing hotspots and growth strategies
More Research Reports >>
Click here to get the FierceVaccines email newsletter for FREE!
Comments (1) | Post a comment